C4 Therapeutics Hits New 52-Week High of $4.59, Marking Significant Milestone

C4 Therapeutics, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 4.59 on June 1, 2026. This achievement marks a notable increase from its 52-week low of USD 1.27, reflecting a substantial upward movement in the stock's performance over the past year. Despite this recent high, C4 Therapeutics has experienced a 1-year performance decline of 9.13%, contrasting sharply with the S&P 500's impressive gain of 28.56% during the same period. The company's market capitalization stands at USD 266 million, indicating its microcap status within the industry. Financial metrics reveal that C4 Therapeutics is currently loss-making, with a return on equity of -70.17% and a debt-to-equity ratio of -1.20. The stock does not offer a dividend yield, and its price-to-book ratio is recorded at 1.73. As C4 Therapeutics continues to navigate the competitive landscape of pharmaceuticals and biotechnology, this recent price milestone highlights its current market position.